--- title: "Selank" canonical_url: https://bestpeptidecalculator.app/library/selank description: "Synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a stabilising tail, developed in Russia as an anxiolytic and most often used intranasally. It has been studied for anxiety without the sedation or dependence associated with benzodiazepines, and retains some immune-modulating activity from its tuftsin origin. Not FDA-approved; the supporting clinical literature is largely Russian-language." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Selank Selank (also called Tuftsin analog or Thr-Lys-Pro-Arg-Pro-Gly-Pro) is an anxiolytic tuftsin analog in the Neuromodulator class. Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation. Synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a stabilising tail, developed in Russia as an anxiolytic and most often used intranasally. It has been studied for anxiety without the sedation or dependence associated with benzodiazepines, and retains some immune-modulating activity from its tuftsin origin. Not FDA-approved; the supporting clinical literature is largely Russian-language. Also known as: Tuftsin analog, Thr-Lys-Pro-Arg-Pro-Gly-Pro. Categories: Cognitive, Experimental. ## Classification - Type: Anxiolytic tuftsin analog / research - Mechanism class: Neuromodulator - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation. Reported activity in animal and small human studies centres on anxiolysis without sedation or dependence: it has been described as modulating GABA-A receptor expression and monoamine turnover, and as inhibiting enkephalin-degrading enzymes, which raises endogenous enkephalin tone. Its tuftsin ancestry also gives it reported immune-modulating activity, including effects on interleukin-6. Most of the literature is Russian-language, where it is used clinically for anxiety disorders; it has no FDA-approved use and independent replication is limited. Targets: GABAergic systems, Enkephalin metabolism. Origin: Synthetic Thr-Lys-Pro-Arg-Pro-Gly-Pro. ## Properties - Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro - Length: 7 - Molecular formula: C33H57N11O9 - Molecular weight: ≈751.9 g/mol - CAS number: 129954-34-3 - Half-life: Not established (varies by route; nasal studied in RU) - Studied routes: Intranasal ## Evidence - Evidence level: Limited Human Evidence - Highest documented: Early or uncontrolled human studies - Human trials: 3 - Controlled human trials: 0 - Preclinical sources: 0 - Latest source: 2015 No human dose is established for this compound. Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. 2015. Human study (early or uncontrolled). Population: Patients with anxiety disorders. Anxiety symptom severity [Source](https://pubmed.ncbi.nlm.nih.gov/26356395/) 2. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. 2014. Human study (early or uncontrolled). Population: Patients with anxiety disorders. Anxiolytic effect and tolerability versus phenazepam [Source](https://pubmed.ncbi.nlm.nih.gov/25176261/) 3. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. 2008. Human study (early or uncontrolled). Population: Patients with anxiety disorders. Efficacy and mechanisms [Source](https://pubmed.ncbi.nlm.nih.gov/18454096/) ## Safety Side effects: Nasal irritation (intranasal); Fatigue. Risks: Not FDA-approved. Human safety basis: Limited human reports Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use.. ## Regulatory status Selank is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - Availability: Research-Only ## Frequently asked questions ### What is Selank? Synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a stabilising tail, developed in Russia as an anxiolytic and most often used intranasally. It has been studied for anxiety without the sedation or dependence associated with benzodiazepines, and retains some immune-modulating activity from its tuftsin origin. Not FDA-approved; the supporting clinical literature is largely Russian-language. Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation. ### What are the side effects of Selank? Selank has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include nasal irritation (intranasal) and fatigue. This is reference information, not medical advice. ### How does Selank work? Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation. Reported activity in animal and small human studies centres on anxiolysis without sedation or dependence: it has been described as modulating GABA-A receptor expression and monoamine turnover, and as inhibiting enkephalin-degrading enzymes, which raises endogenous enkephalin tone. ### Is Selank FDA approved? No. Selank is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators. ### What is the half-life of Selank? Reported half-life for Selank is Not established (varies by route; nasal studied in RU). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied. ### What is the amino acid sequence of Selank? Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, giving a chain of 7 amino acids. Its molecular formula is C33H57N11O9. ### What peptides are similar to Selank? Compounds most often compared with Selank include Semax, N-Acetyl Semax Amidate, Adamax and Cerebrolysin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [\[Optimization of the treatment of anxiety disorders with selank\] — Zh Nevrol Psikhiatr Im S S Korsakova, 2015](https://pubmed.ncbi.nlm.nih.gov/26356395/) - [\[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia\] — Zh Nevrol Psikhiatr Im S S Korsakova, 2008](https://pubmed.ncbi.nlm.nih.gov/18454096/) - [\[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders\] — Zh Nevrol Psikhiatr Im S S Korsakova, 2014](https://pubmed.ncbi.nlm.nih.gov/25176261/) - [Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bull Exp Biol Med, 2022](https://pubmed.ncbi.nlm.nih.gov/36322304/) - [The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress — Curr Rev Clin Exp Pharmacol, 2021](https://pubmed.ncbi.nlm.nih.gov/32621722/) Note: Dose figures are left out of this Markdown version. See the cited sources.